MAP2K7 and melanoma: Several years ago, BRAF inhibitors such as vemurafenib, dabrafenib, and encorafenib revolutionized the treatment of melanoma, nowadays given in combination with MEK inhibitors like cobimetinib, trametinib and binimetinib.